GleamWall
中文EN

TVRD Tvardi Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1346830 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.7%
TTM EPS YoY64.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-123.1%
ROA-85.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets34.3%
Debt / equity0.00x
Current ratio2.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue——————$2.57M$1.46M
R&D expense$4.47M$4.00M$4.91M$5.49M$3.60M$5.81M$3.11M$8.60M
SG&A expense$1.85M$2.63M$2.14M$2.10M$2.33M$3.06M$1.24M$2.20M
Operating income-$6.33M-$6.63M-$7.05M-$7.59M-$5.94M-$8.87M-$4.35M-$10.80M
Interest expense————$0$93,000$558,000—
Income tax——————$0-$398,000
Net income-$6.12M-$6.46M-$6.80M-$7.28M-$5.53M$4.17M-$9.58M-$12.71M
EBITDA-$6.30M-$6.61M-$7.03M-$7.56M-$5.91M-$8.82M-$4.33M-$10.78M
EPS (basic)-0.48-0.69-0.73—-0.590.51-3.72—
EPS (diluted)-0.48-0.69-0.73—-0.59-1.00-3.72—
Dividends declared per share0.000.000.000.000.00———
Weighted avg. shares (diluted)12.65M9.38M9.38M—9.38M8.46M2.58M—
Balance sheet
Cash & equivalents$22.27M$15.77M$19.85M$20.73M$21.42M$20.65M$11.44M$31.61M
Short-term investments$0—$5.13M$10.08M$15.04M$20.35M——
Receivables——————$1.23M$407,000
Inventory——————$900,000$900,000
Current assets$23.13M$17.07M$25.33M$31.54M$38.44M$43.13M—$31.69M
PP&E, net$28,000$36,000$44,000$52,000$60,000$68,000—$84,000
Intangibles$275,000$291,000$306,000$322,000$338,000$354,000—$385,000
Total assets$23.53M$17.52M$25.82M$32.07M$39.02M$43.75M$38.95M$35.20M
Current liabilities$8.08M$9.11M$11.26M$11.04M$11.04M$10.68M$1.20M$10.37M
Total liabilities$8.08M$9.13M$11.31M$11.13M$11.15M$10.82M$47.02M$40.83M
Shareholders' equity$15.46M$8.38M$14.51M$20.95M$27.87M$32.93M-$100.62M-$91.13M
Shares outstanding13.35M9.38M9.38M9.38M9.38M9.37M1.52M2.57M
Cash flow statement
Operating cash flow-$6.38M-$9.23M-$5.86M-$5.68M-$4.26M-$8.87M-$7.69M-$4.83M
Capital expenditure———————$0
Free cash flow———————-$4.83M
Investing cash flow$0$5.14M$4.98M$5.00M$5.35M-$9.55M-$10.88M$5.00M
Financing cash flow———$1,000-$322,000$22.02M-$1.60M$27.01M
Depreciation & amortization$24,000$23,000$24,000$24,000$24,000$47,000$24,000$24,000
Stock-based compensation$386,000$335,000$370,000$353,000$339,000$627,000$80,000$79,000

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.